Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Synnott, Naoise C; Bauer, Matthias R; Madden, Stephen; Murray, Alyson; Klinger, Rut; O'Donovan, Norma; O'Connor, Darran; Gallagher, William M; Crown, John; Fersht, Alan R; Duffy, Michael J

Synnott, Naoise C; Bauer, Matthias R; Madden, Stephen; Murray, Alyson; Klinger, Rut; O'Donovan, Norma; O'Connor, Darran; Gallagher, William M; Crown, John; Fersht, Alan R; Duffy, Michael J.

Synnott NC; UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
Bauer MR; Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.
Madden S; Population Health Sciences, Department of Psychology, Royal College of Surgeons in Ireland, Dublin, Ireland.
Murray A; UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
Klinger R; UCD School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin 4, Ireland.
O'Donovan N; National Institute for Cellular Biotechnology (NICB), Dublin City University, Dublin, Ireland.
O'Connor D; Department of Molecular & Cellular Therapeutics, Royal College of Surgeons Ireland, Dublin, Ireland.
Gallagher WM; UCD School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin 4, Ireland.
Crown J; Department of Medical Oncology, St Vincent's University Hospital, Dublin 4, Ireland.
Fersht AR; Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.
Duffy MJ; UCD School of Medicine, University College Dublin, Dublin 4, Ireland; UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin 4, Ireland. Electronic address: MICHAEL.J.DUFFY@UCD.IE.

Cancer Lett ; 414: 99-106, 2018 02 01.

Article en En | MEDLINE | ID: mdl-29069577

Asunto(s)

Antineoplásicos/farmacología; Apoptosis/efectos de los fármacos; Proliferación Celular/efectos de los fármacos; Proteínas Mutantes/antagonistas & inhibidores; Proteína p53 Supresora de Tumor/antagonistas & inhibidores; Apoptosis/genética; Línea Celular Tumoral; Proliferación Celular/genética; Femenino; Perfilación de la Expresión Génica; Regulación Neoplásica de la Expresión Génica/efectos de los fármacos; Ontología de Genes; Humanos; Células MCF-7; Proteínas Mutantes/genética; Proteínas Mutantes/metabolismo; Pirimidinas/farmacología; Sulfonas/farmacología; Neoplasias de la Mama Triple Negativas/genética; Neoplasias de la Mama Triple Negativas/metabolismo; Neoplasias de la Mama Triple Negativas/patología; Proteína p53 Supresora de Tumor/genética; Proteína p53 Supresora de Tumor/metabolismo

Palabras clave

2-sulfonylpyrimidine PK11007; APR-246; PRIMA-1MET; breast cancer; mutant p53; triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Apoptosis / Proliferación Celular / Proteínas Mutantes / Antineoplásicos Límite: Female / Humans Idioma: En Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google